Advertisement
Advertisement

PTHS

PTHS logo

Pelthos Therapeutics Inc.

23.14
USD
Sponsored
-0.19
-0.80%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

23.02

-0.11
-0.48%

PTHS Earnings Reports

Positive Surprise Ratio

PTHS beat 1 of 5 last estimates.

20%

Next Report

Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
--
/
--
Implied change from Q-- -- (Revenue/ EPS)
--
/
--

Pelthos Therapeutics Inc. earnings per share and revenue

On Nov 13, 2025, PTHS reported earnings of -5.30 USD per share (EPS) for Q3 25, missing the estimate of -0.56 USD, resulting in a -844.74% surprise. Revenue reached 7.41 million, compared to an expected 4.47 million, with a 65.79% difference. The market reacted with a -7.27% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
logo
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
logo
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
logo
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
logo
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
logo
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
logo
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
logo
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
logo
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
logo
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
For Q3 2025, Pelthos Therapeutics Inc. reported EPS of -$5.30, missing estimates by -844.74%, and revenue of $7.41M, 65.79% above expectations.
The stock price moved down -7.27%, changed from $37.40 before the earnings release to $34.68 the day after.
The next earning report is scheduled for --.
Based on -- analysts, Pelthos Therapeutics Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement